that F31 regulation 214(1) or (2) of the 2012 Regulations shall have effect subject to such exemptions as may be specified in the order F1F32 or, in the case of an appropriate practitioner, other than a doctor or dentist, such modifications as may be so specified ;

that, for the purpose of F37 regulation 214(1) of the 2012 Regulations , a medicinal product shall not be taken to be sold or supplied in accordance with a prescription given by an appropriate practitioner unless such conditions as are prescribed by the order are fulfilled.

give a prescription for a medicinal product falling within a description or class specified in the order;

administer any such medicinal product; or

give directions for the administration of any such medicinal product,

the Commission; or

an expert committee appointed by the Ministers, or by one of them acting alone.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

to which subsection (2) of this section applies;

is likely to present a direct or indirect danger to human health, even when used correctly, if used without the supervision of a doctor or dentist; or

is frequently and to a very wide extent used incorrectly, and as a result is likely to present a direct or indirect danger to human health; or

contains substances or preparations of substances of which the activity requires, or the side-effects require, further investigation; or

is normally prescribed by a doctor or dentist for parenteral administration.

contains a substance which is listed in any of Schedules I, II or IV to the Narcotic Drugs Convention (where the product is not a preparation listed in Schedule III to that Convention); or

contains a substance which is listed in any of Schedules I to IV of the Psychotropic Substances Convention (where the pro duct is not a preparation which may be exempted from measures of control in accordance with paragraphs 2 and 3 of article 3 of that Convention); or

contains a substance which, by reason of its novelty or properties, might fall within paragraph (c) above, but as to which there is insufficient information available to determine whether it does so fall; or

by reason of its pharmaceutical characteristics or novelty, or in the interests of public health, is reserved for treatments which can only be followed in a hospital; or

is used in the treatment of conditions which must be diagnosed in a hospital or in an institution with special diagnostic facilities (although administration and subsequent supervision may be carried out elsewhere); or

is intended for outpatients but may produce very serious sideeffects which would require a prescription drawn up as required by a specialist and special supervision throughout the treatment.

the maximum single dose;

the maximum daily dose;

the strength of the product;

its pharmaceutical form;

its packaging; or

such other circumstances relating to its use as may be specified in the determination.

prohibit the sale or supply, or the importation, of medicinal products of any description, or falling within any class, specified in the order, or (in such manner as may appear to them to be sufficient to identify the products in question) designate particular medicinal products and prohibit the sale or supply, or the importation, of those particular products;

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

if the organisation have given notice of their desire to be heard, the F24Ministers shall arrange for them to have an opportunity of appearing before, and being heard by, the F9appropriate committee, or

if they have made representations in writing, the F24Ministers shall refer those representations to the F9appropriate committee,

the appropriate committee have not considered the proposal to make the order, or

the order is made contrary to the advice of the appropriate committee,

the Commission; or

an expert committee appointed by the Ministers, or by one of them acting alone.

the addition or abstraction was not carried out fraudulently, and did not injuriously affect the composition of the product, and

the product was sold having attached to it, or to a container or package in which it was sold, a conspicuous notice of adequate size and legibly printed, specifying the substance added or abstracted.

in those provisions any reference to sale included a reference to supply and (except as provided by the following paragraph) any reference to the purchaser included a reference to the person (if any) for whom the product was prescribed by the practitioner, and

in subsection (1) of this section, for the words “demanded by the purchaser", there were substituted the words “specified in the prescription".